Effects of NRA0045, NRA0160, and NRA0215 on regional Fos-like immunoreactivity in the rat brain

General Pharmacology

Volumn 32, Issue 6, 1999, Pages 637-646

  Kawashima, N ^a   Nakamura, A ^a   Okuyama, S ^a   Chaki, S ^a   Tomisawa, K ^a  

^a Medicinal Research Laboratories   (Japan)

Author keywords

Dopamine D4 receptors; Fos like immunoreactivity; Medial prefrontal cortex; NRA0045; NRA0160; NRA0215

Indexed keywords

2 AMINO 4 (4 FLUOROPHENYL) 5 [1 [4 (4 FLUOROPHENYL) 4 OXOBUTYL] 3 PYRROLIDINYL]THIAZOLE; 2 CARBAMOYL 4 (4 FLUOROPHENYL) 5 [2 [4 (3 FLUOROBENZYLIDENE)PIPERIDIN 1 YL]ETHYL]THIAZOLE; 2 CARBAMOYL 4 PHENYL 5 [2 [4 (4 FLUOROBENZYLIDENE)PIPERIDIN 1 YL]ETHYL] THIAZOLE; ALPHA 1 ADRENERGIC RECEPTOR; CLOZAPINE; DOPAMINE 4 RECEPTOR; HALOPERIDOL; PROTEIN C FOS; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BRAIN REGION; CONTROLLED STUDY; DRUG EFFECT; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN CHEMISTRY; CLOZAPINE; CORPUS STRIATUM; HALOPERIDOL; IMMUNOHISTOCHEMISTRY; MALE; NUCLEUS ACCUMBENS; PIPERIDINES; PREFRONTAL CORTEX; PROTO-ONCOGENE PROTEINS C-FOS; PYRROLIDINES; RATS; RATS, WISTAR; THIAZOLES;

EID: 0033036467     PISSN: 03063623     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-3623(98)00241-9     Document Type: Article

References (51)

1. Baldessarini R.J., Tarsey D. Dopamine and the pathophysiology of dyskinesias induced by antipsychotic compounds. Ann Rev Neurosci. 3:1980;23-41.
2. Baldessarini R.J., Frankenburg F.R. Clozapine. a novel antipsychotic agent N Engl J Med. 324:1991;746-754.
3. 123I]-iodosulpride Synapse. 19:1995;1-13.
4. Boyer P., Lecrubier Y., Puech A.J. Treatment of positive and negative symptoms. pharmacological approaches Mod Proc Pharmacopsychiatry. 24:1990;152-174.
5. Bristow L.J., Kramer M.S., Kulagowski J., Patel S., Ragan C.I., Seabrook G.R. Schizophrenia and L-745,870, a novel dopamine D4 receptor antagonist. Trends Pharmac Sci. 18:1997;186-188. a.
6. Bristow L.J., Collinson N., Cook G.P., Curtis N., Freedman S.B., Kulagouwski J.J., Leeson P.D., Patel S., Rangan C.I., Ridgill M., Saywell K.L., Tricklebank M.D. L-745,870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests. J Pharmac Exp Ther. 283:1997;1256-1263. b.
7. Carelli R.M., West M.O. Representation of the body by single neurons in the dorsolateral striatum of the awake, unrestrained rat. J Comp Neurol. 309:1991;231-249.
8. Chouinard G., Jones B., Remington G., Bloom D., Addington D., Macewan G.W., Labelle A., Beauclair L., Arnott W. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmac. 13:1993;24-40.
9. Creese I., Burt D.R., Snyder S.H. Dopamine receptor binding predicts clinical and pharmacological properties of antischizophrenic drugs. Science. 192:1976;481-483.
10. Deutch A.Y., Duman R.S. The effects of antipsychotic drugs on Fos protein expression in the prefrontal cortex. cellular localization and pharmacological characterization Neuroscience. 70:1996;377-389.
11. Deutch A.Y., Lee M.C., Iadarole M.J. Regionally specific effects of atypical antipsychotic drugs on striatal fos expression. the nucleus accumbens shell as a locus of antipsychotic action Mol Cell Neurosci. 3:1992;332-341.
12. Dragunow M., Robertson G.S., Fuall R.L.M., Robertson H.A., Jansen K. D2 dopamine receptor antagonists induce Fos and related proteins in rat striatal neurons. Neuroscience. 37:1990;287-294.
13. Fink-Jensen A., Kristensen P. Effects of typical and atypical neuroleptics on Fos protein expression in the rat forebrain. Neurosci Lett. 182:1994;115-118.
14. 2 receptor blockade to haloperidol. Neurosci Lett. 194:1995;77-80.
15. Geyer M.A., Swerdlow N.R., Mansbach R.S., Braff D.L. Startle response models of sensorimotor gating and habituation deficits in schizophrenia. Brain Res Bull. 25:1990;485-498.
16. Guo N., Klitenick M.A., Tham C.-S., Fibiger H.C. Receptor mechanisms mediating clozapine-induced c-fos expression in the forebrain. Neuroscience. 65:1995;747-756.
17. Hirschowitz J., Hitzemann R., Buur G., Maurset A. A new approach to dose reduction in chronic schizophrenia. Neuropsychopharmacology. 5:1991;103-113.
18. 3 receptor antagonist GR103691 with typical and atypical neuroleptics Eur J Pharmac. 318:1996;283-293.
19. Kramer, M.S., Last, B., Getson, A., Reines, S.A., D4 Dopamine Antagonist Group, 1997. The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. Arch Gen Psychiatry 54, 567-572.
20. 2-like receptor antagonist, on immediate early gene expression in the rat forebrain. Neuropsychopharmacology. 17:1997;27-33.
21. Levinson D.F. Pharmacologic treatment of schizophrenia. Clin Ther. 13:1991;326-352.
22. MacGibbon G.A., Lawlor P.A., Bravo R., Dragunow M. Clozapine and haloperidol produce differential pattern of immediate early gene expression in rat caudate-putamen, nucleus accumbens, lateral septum and islands of Calleja. Mol Brain Res. 23:1994;21-32.
23. 4 receptor antagonists reverse apomorphine-induced blockade of prepulse inhibition. Psychopharmacology. 135:1998;194-200.
24. i values. J Pharmac Exp Ther. 251:1989;238-246.
25. Meltzer H.Y., Zhang Y., Stockmeier C.A. Effect of amperozide on rat cortical 5-HT2 and striatal and limbic dopamine D2 receptor occupancy. implications for antipsychotic action Eur J Pharmac. 216:1992;67-71.
26. Merchant K.M., Dorsa D.M. Differential induction of neurotensin and c-fos gene expression by typical and atypical antipsychotics. Proc Natl Acad Sci USA. 90:1993;3447-3451.
27. 3 receptors Cereb Cortex. 6:1996;561-570. a.
28. 4 receptor selective antagonist. J Pharmac Exp Ther. 279:1996;1392-1403. b.
29. Miller J.C. Induction of c-fos mRNA expression in rat striatum by neuroleptic drugs. J Neurochem. 54:1990;1453-1455.
30. 3 receptor. Bioorg Med Chem Lett. 5:1995;219.
31. Nguyen T.V., Kosofsky B.E., Birnbaum R., Cohen B.M., Hyman S.E. Differential expression of c-Fos and Zif268 in rat striatum after haloperidol, clozapine, and amphetamine. Proc Natl Acad Sci USA. 89:1992;4270-4274.
32. 4 receptor antagonists. receptor-binding and neuropharmacological profiles Soc Neurosci Abstr. 22:1996;1771.
33. 2A receptor and alpha-1 adrenoceptor antagonist (R)-(+)-2-amino-4-(4-fluorohenyl)-5-[1-[4-(4-fluorophenyl)-4-oxobutyl] pyrrolidin-3-yl]thiazole (NRA0045). J Pharmac Exp Ther. 282:1997;56-63. a.
34. 4 receptor antagonists (3). benzylydenepiperidinoethylthiazole derivatives Am Chem Soc Abstr MEDI. 017:1997;. b.
35. 2A receptor antagonist, in rats. Br J Pharmac. 121:1997;515-525. c.
36. Pisa M. Motor functions of the striatum of the rat. critical role of the lateral region in tongue and forelimb reaching Neuroscience. 24:1988;453-463.
37. Reynolds G.P. Developments in the compound treatment of schizophrenia. Trends Pharmac Sci. 13:1992;116-121.
38. Robertson G.S., Fibiger H.C. Neuroleptics increase c-fos expression in the forebrain. contrasting effects of haloperidol and clozapine Neuroscience. 46:1992;315-328.
39. Robertson G.S., Fibiger H.C. Effects of olanzapine on regional c-fos expression in rat forebrain. Neuropsychopharmacology. 14:1996;105-110.
40. Robertson G.S., Matsumura H., Fibiger H.C. Induction patterns of neuroleptic-induced Fos-like immunoreactivity as predictors of atypical antipsychotic activity. J Pharmac Exp Ther. 271:1994;1058-1066.
41. 4 Neuropsychopharmacology. 7:1992;261-284.
42. Seeman P. Dopamine receptors. clinical correlates Bloom F.E., Kupfer D.V. Psychopharmacology. the fourth generation of progress:1995;295-302 Raven Press, New York.
43. Seeman P., Van Tol H.H.M. Dopamine receptor pharmacology. Trends Pharmac Sci. 15:1994;264-270.
44. Seeman P., Lee T., Chan-Wong M., Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature. 261:1976;717-719.
45. Snyder S.H. Dopamine receptors, neuroleptics and schizophrenia. Am J Psychiatry. 138:1981;461-468.
46. 2 receptors. J Pharmac Exp Ther. 266:1993;1374-1384.
47. Swerdlow N.R., Braff D.L., Taaid N., Geyer M.A. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry. 51:1994;139-154.
48. Vahid-Ansari F., Robertson G.S. 7-OH-DPAT differentially reverses clozapine- and haloperidol-induced increases in Fos-like immunoreactivity in the rodent forebrain. Eur J Neurosci. 8:1996;2605-2611.
49. 4 receptor with high affinity for the antipsychotic clozapine. Nature. 350:1991;610-614.
50. Wagstaff A.J., Bryson H.M. Clozapine. a review of its pharmacological properties and therapeutic use in patients with schizophrenia who are unresponsive to or intolerant of classical antipsychotic agents CNS Drugs. 4:1995;370-400.
51. Weinberger D.R. Schizophrenia and the frontal lobe. Trends Neurosci. 8:1988;367-370.